The total return over the past 12 months is -27.62% vs. +16.94% for the S&P 500. So far it's up -43.42% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (27.62%) | (29.47%) | (21.98%) | N/A | N/A | N/A |
| Total Return CAGR | (27.62%) | (29.47%) | (21.98%) | N/A | N/A | N/A |
| Revenue CAGR | (93.55%) | N/A | +172.50% | N/A | N/A | N/A |
| Net Income CAGR | (542.97%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (191.35%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (187.20%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Keros Therapeutics, Inc. (KROS)
| Year | Start price | End price | KROS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $20.36 | $11.52 | (43.42%) | +14.51% | (57.93%) |
| 2025 | $15.83 | $20.36 | +28.62% | +17.72% | +10.90% |
| 2024 | $39.76 | $15.83 | (60.19%) | +24.89% | (85.08%) |
| 2023 | $48.02 | $39.76 | (17.20%) | +26.19% | (43.39%) |
| 2022 | $58.51 | $48.02 | (17.93%) | (18.17%) | +0.24% |
| 2021 | $70.54 | $58.51 | (17.05%) | +28.74% | (45.79%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
